News
The socioeconomic revolving door of 30-day heart failure readmissions
Racial disparities in 30-day HF readmissions stem partly from variation in economic status of residential neighborhoods, regardless of hospital...
News
‘Cautious’ DOAC underdosing in AFib may push mortality higher
Risk-averse clinicians might be doing more harm than good by prescribing direct oral anticoagulants at lower-than-recommended dosages in hope of...
News
Minidose edoxaban may safely cut AFib stroke risk in the frail, very elderly
Those who took the factor Xa inhibitor edoxaban (Savaysa) at the off-label dosage of 15 mg once daily showed a two-thirds drop in risk for stroke...
News
EXPLORER trial hints at potential new drug option in obstructive hypertrophic cardiomyopathy
Mavacamten, which seemed to improve function and alleviate symptoms in the short trial, is the first potential drug for the disorder that...
News
Vast underdiagnosis of monogenic CV disease seen in cath referrals
Most such patients with a heart disease–linked gene variant and who showed clinical signs of the disease did not receive a diagnosis, in a study...
News
All NSAIDs raise post-MI risk but some are safer than others: Next chapter
A new cohort analysis extends NSAID cautions in high-CV-risk patients to a Korean population. Some question whether the steep climbs in risk seen...
News
Heart damage even after COVID-19 ‘recovery’ evokes specter of later heart failure
Recovery from acute COVID-19 isn’t necessarily the end of it, clearly. Two reports aim to clarify how SARS-CoV-2 can directly invade the heart and...
News
SCD-HeFT 10-year results: Primary-prevention ICD insights in nonischemic heart failure
The trial’s most recent results add to ongoing controversy – fueled by DANISH and other studies – about whether primary-prevention ICDs prolong...
News
Dapagliflozin benefits low-EF heart failure regardless of diuretic dose: DAPA-HF
The trial that turned an SGLT2 inhibitor into a heart failure drug also has clues to mechanisms behind the observed benefits. Contrary to early...
News
VICTORIA results deepen mystery of vericiguat in low-EF heart failure
The novel drug didn’t seem to affect ventricular function in the high-risk heart failure patients, “creating a dissociation between the surrogate...
News
S-ICD ‘noninferior’ to transvenous-lead ICD in head-to-head PRAETORIAN trial
Younger patients without heart failure “are the kind of patient who you would probably lean very strongly toward for an S-ICD rather than a...
News
VICTORIA: Vericiguat seen as novel success in tough-to-treat, high-risk heart failure
The relative risk reduction was modest, but experts say the benefit in absolute terms was remarkable for already well-treated patients.
